Treatment of in-stent restenosis using sirolimus-eluting stents: ISR II registry  by Commeau, Philippe et al.
JACC March 19,2003 ABSTRACTS - Angiography & Interventional Cardiology 53A 
Clinical Outcomes BE59 UFH.83 P value 
Death , n% 0 (/59) 0 (O/83) NS 
Major Stroke, n% 0 (O/59) 1.2 (l/83) 1 .oo 
Minor stroke, n% 0 (O/59) 0 (O/83) NS 
Hematoma > 5cm (%) 1.7 (l/59) 3.6(3/83) 0.64 
Pseudoaneurysm 0 (O/59) 2.4 (2/83) 0.51 
Transfusion (%) 0 (O/59) 8.6 (7/81) 0.02 
Vascular Complication 1.7 (1159) 4.9 (4/81) 0.39 
Conclusion: The use of B during carotid stenting is feasible, safe and may be an attrac- 
tive alternative to UFH in view of lower vascular complications without an increase of 
neurologic events. 
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Mariin Leon, Jeffrey Moses, Mark-Claude Morice. Egon Wulferl, David Holmes, lnstitut 
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Background. Sirolimus-eluting stents have been associated with a near complete aboli- 
tion of the restenosis process. In the era of drug-eluting stents, the technical approach to 
bifurcation lesions is crucial. 
Methods. A randomized study was set up to assess the results of the CYPHER stent 
(Sirolimus-eluting stent) in the treatment of bifurcation lesions. Patients were randomized 
to receive a CYPHER stent in the main branch with provisional stenting in the side 
branch or systematic stenting of both branches with 2 CYPHER stents. The technique 
applied was left to the operator’s judgment. 
Results. From June 2001 to April 2002,86 patients were enrolled in 5 centers. The pop- 
ulation consisted of 80% male pts, mean age 63*10 y, 22% diabetic. To date 47 tines 
views of the acute phase and 6.month follow-up have been analyzed. 3 different tech- 
niques were used: 1) stent in main branch only, followed by kissing balloon, 2) T stenting 
with kissing balloon, 3) modified Y stenting. Restenosis rate defined as stenosis at follow- 
up 2 50% in the main or side branch is shown in the table below: 
Conclusion. Use of Sirolimus-eluting stents to treat bifurcation lesions is an eflective 
technique and reduces restenosis as compared to earlier results with other stents. Stent- 
ing of the main branch, followed by kissing balloon inflation should be the preferred tech- 
nique whenever possible as it seems to provide the most favorable results. 
Technique 12 3 
Patients (n) 13 13 16 
Restenosls in side branch (n) 1 3 3 
Restenosis in main branch (n) 0 0 1 
Restenosis in both branches (n) 0 1 1 
Restenosis rate (%) 7 30.8 31.2 
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839FO-3 Bifurcational Coronary Artery Lesion Treatment With 
Rapamicine-Eluting Stents: Results From a Single 
Center Experience 
Flavio Airoldi Vassilis Spanos, Goran Stankovic, Carlo Di Mario, Alaide Chieffo, Carlo -I 
Briguori, Francesco Liistro, Mauro Carlino, Maneo Montorfano, Massimo Ferraro, 
Antonio Colombo, Emo Centro Cuore, Milan, Italy. San Raffaele Hospital, Milan, Italy 
Methods we report the immediate and mid term results in a series of 79 consecutive 
bifurcational lesions (BL) treated with rapamtcine eluting stems (Cypher, Cordis, J &J, 
Miami, FI). Lesions were located as follows: 41 on LAD-diagonal branch; 1 on LAD-sep- 
tal; 25 On LCX-obtuse marginal; 10 on RCA; 2 on LM-LCX-LAD. Result: Angioplasty with 
only one stent on the main branch was performed in 23% of lesions; in the remaining 
77% Of BL, both branches were stented with the modified T-stenting technique. Ilb-llla 
receptor antagonists were used in 25% of the cases. Technical success was reached in 
all cases. During the hospital stay no death neither urgent target vessel revascularization 
occurred; 5 non-Q myocardial infarction (6.3%) were recorded. After the procedure all 
the patients were treated with double antiplatelet therapy for at least 3 months. During 
the first month, one patient died. All the eligible patients (n=24) underwent a B-months 
angiographic follow-up as reported in table. Binary restenosis (~50%) occurred in 2 BL 
(8%) and TVR was performed in 2 cases (4%). The complete clinical and angiographic 
follow-up will be available for the time of presentation. Conclusion BL stenting with 
rapamicine eluting stems is associated to a high rate of technical success. One month 
follow-up has showed a low incidence of subacute thrombosis. Preliminary angiographic 
follow-up data indicate a low rate of restenosis. However, the definitive judgment of this 
treatment must be confirmed at the end of the follow-up. 
p=O.Ol for paired t-test comparisons to baseline values 
Basal ref., mm Basal MLD, mm Post MLD, mm FU MLD, mm 
Main branch 2.81*0.39 0.88*0.41 2.79+0.44’ 2.56t0.61’ 
Side brach 2.08ztO.38 0.9liO.45 2.29+0.41’ 1.85r0.78 
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Restenosis in the Real World: Preliminary Results From 
the Rapamycin-Eluting Stent Evaluated at Rotterdam 
Cardiology Hospital (RESEARCH) Registry 
Francesco Saia, Pedro A. Lemos, Muzaffer Degertekin, Evelyn Regar, Chourmouzios A. 
Arampatzis, Chi-Hang Lee, Kengo Tanabe, Pim de Feyter. Willem J. van der Giessen. 
George Sianos, Pieter Smits, Ron T. van Domburg, Patrick W. Serruys, Erasmus MC, 
Thoraxcenter, Rotterdam, The Netherlands 
Background: In-stent restenosis (ISR) represents a significant clinical problem following 
stent implantation. Brachytherapy is to date the only effective treatment, but it is not free 
from drawbacks and presents a not neglegible number of failures. Preliminary studies 
have shown that sirolimus-eluting stents @ES) are safe and effective for treatment of 
ISR. We are testing the efficacy of this strategy in daily practice. 
Methods: Since 16th April 2002 all patients undergoing a PTCA at our institution have 
been treated with SE.?, irrespective of clinical presentation and lesion morphology, and 
enrolled in the RESEARCH registry. Exclusion criteria included participation to another 
trial or unavailability of an adequately sized SES. The Registry will be closed on the 15th 
of October 2002. All patients will receive 6 and 1 P-month clinical follow-up as well as a 6. 
month angiography. Cost-effectiveness will be compared to the historical cohort of 
patients treated in the preceding six months. 
Results: After 4 months from the beoinnino of the studv. 382 oatlents had at least one , 
SES implanted (76.7% of all PTCA patients-in the period). Among them, 37 (9.7%) were 
treated for ISR 140 les~onsl. Clinical oresentation was stable anoina for 28 (75.6%) 
patients, unstable angina fo; 8 (21.6%; and acute MI for 1 (2.7%).“23 patients {62.2%j 
had multi-vessel disease. Target vessel was kfl anterior descending in 14 cases (35%), 
circumflex in 8 (20%), right coronary in 11 (27.5%), left main in 3 (7.5%), and CABG in 4 
(10%). Lesions were classified as focal (11, 27.5%), diffuse (9, 22.5%), proliferative (12, 
30%) and totally occlusive (8, 20%). Five patients (18.5%) had been previously treated 
with brachytherapy. A total of 66 SES were implanted (average 1.78ipatient). of which 9 
(13.6%) equal or less than 2.5 mm in diameter. Average stent lenght per patient was 
31.82 23.1 mm (median 26 mm; range 8-92 mm). All patients received clopidogrel for a 
minimum of two months. Procedural success was achieved in 36137 patients (97.3%). 
Conclusions: We are evaluating the effectiveness of SES to treat ISR. Procedural 
results are satisfactory. Short- and medium-term clinical and angiographic follow-up is 
needed lo draw further conclusions. 
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839FO-5 Treatment of In-Stent Restenosis Using Sirolimus- 
Eluting Stents: ISR II Registry 
Philippe Commeau Paul T. Barragan, Pierre 0. Roquebert, Jean L. Bouvier, Bertrand 
Comet, Gilles Macaluso, CHP Beauregard, Marseille, France 
In-Stent Restenosis (ISR) remains the major limitation of percutaneous coronary inter- 
vention. The efficacy of Sirolimus-eluting (SE) stent for treatment of ISR is still under 
evaluation. 
Twenty three patients (pts) (mean age : 64.0 * 11 .l yrs) with 34 ISR lesions (mean 1.6 * 
0.7 lesion per patient) in native coronary arteries were treated with 8 or 18mm SE stents 
(mean stent length 19.0 * 9.5 mm). Sixteen pts were male, 7 diabetic, 20 treated for 
hypercholesterolemia and 5 were in unstable angina. Forty eight stents were success- 
fully implanted ( 39% RCA, 33% LAD, 28 % LCX) at 16.1 * 3.2 bars. Procedural QCA 
indicated a reference vessel diameter of 2.7 + 0.7 mm. a minimum lumen diameter of 0.8 
f 0.3 mm pre-stent and 2.5 + 0.6 mm post-stent. All patients received Clopidogrel (75mg 
x 2 daily) or Ticlopidine (250mg x 2 daily) for 2 months. One month adverse events 
included 2 non-Q myocardial infarctions : one in-hospital unrelated with the stented 
artery and another due to a subacute thrombotic occlusion of the SE stem at 5 days. 
Repeat angiography will be performed 8 months after the baseline procedure. 
Conclusions : This preliminary ISR II registry shows an early feasibility for the use of SE 
stent to treat ISR. Eight month clinical and angiographic follow-up will be reported in 
March 2003. 
